These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 18287255

  • 1. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
    Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U, ARCTOS Study Investigators.
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
    [Abstract] [Full Text] [Related]

  • 2. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

  • 3. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 4. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
    Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U.
    Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
    [Abstract] [Full Text] [Related]

  • 5. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA, Meyer Reigner S, Tirodkar C, Drozdz D.
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Jun; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 9. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
    Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C.
    Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Aug; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 13. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 14. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.
    Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC, PATRONUS Investigators.
    Nephrol Dial Transplant; 2010 Dec; 25(12):4009-17. PubMed ID: 20522670
    [Abstract] [Full Text] [Related]

  • 15. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.
    Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.
    Drugs Aging; 2009 Dec; 26(8):665-75. PubMed ID: 19685932
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):81-90. PubMed ID: 29097481
    [Abstract] [Full Text] [Related]

  • 17. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 18. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR, Geronemus R, Krause M, Chen CY, Kewalramani R, Stehman-Breen C.
    Curr Med Res Opin; 2009 Jan 03; 25(1):123-31. PubMed ID: 19210145
    [Abstract] [Full Text] [Related]

  • 19. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T.
    Am J Nephrol; 2021 Jan 03; 52(10-11):884-893. PubMed ID: 34569482
    [Abstract] [Full Text] [Related]

  • 20. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
    Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC.
    Nephrol Dial Transplant; 2011 Dec 03; 26(12):3980-6. PubMed ID: 21505096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.